Predicting the Safety and Effectiveness of Inferior Vena Cava Filters (PRESERVE) Trial
The PRESERVE (Predicting the Safety and Effectiveness of Inferior Vena Cava Filters) Trial is the first large-scale, multi-specialty, prospective clinical study to evaluate the use of inferior vena cava (IVC) filters and related follow-up treatment in the United States. With the guidance of the Food and Drug Administration (FDA), the study will help determine how well filters prevent pulmonary embolisms and when retrievable filters should be removed, thus advancing patient safety.
The trial is sponsored by the IVC Filter Study Group Foundation, a joint collaboration between the Society of Interventional Radiology and the Society for Vascular Surgery.
Currently, the study is recruiting patients. For additional information about participating sites, please visit ClinicalTrials.gov.
Two PRESERVE Filters Reach Enrollment Cap
As of January 2018, two PRESERVE filters, Option Elite Retrievable and DENALI have reached their 300 subject cap, and enrollment is closed for these filters. A total of 6 filter manufacturers are participating in the trial to reach the overall goal of 1,800 subjects.
The PRESERVE team encourages sites to keep up the excellent work in enrolling patients into other study filters.
New IVC filter added to PRESERVE Trial
The VenaTech Convertible Filter (B. Braun Interventional Systems Inc.) has been added to the PRESERVE Trial. If your site is using this filter and would like to participate in PRESERVE, please contact Eleanore Moye.
Listen to Matthew Johnson, MD, FSIR, the co-chair of the PRESERVE Steering Committee, discuss the background and current status of this important initiative.